WallStSmart

Stryker Corporation (SYK)vsTela Bio Inc (TELA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 32495% more annual revenue ($25.12B vs $77.06M). SYK leads profitability with a 12.9% profit margin vs -50.6%. SYK earns a higher WallStSmart Score of 65/100 (C+).

SYK

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.18

TELA

Avoid

31

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -5.04
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SYKUndervalued (+16.8%)

Margin of Safety

+16.8%

Fair Value

$393.59

Current Price

$327.65

$65.94 discount

UndervaluedFair: $393.59Overvalued

Intrinsic value data unavailable for TELA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$125.72B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

TELA0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

SYK3 concerns · Avg: 3.7/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TELA4 concerns · Avg: 3.3/10
Price/BookValuation
17.3x4/10

Trading at 17.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$33.90M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.8%2/10

ROE of -6.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.

Bull Case : TELA

TELA has a balanced fundamental profile.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : TELA

The primary concerns for TELA are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 26.98 is elevated, increasing financial risk.

Key Dynamics to Monitor

SYK profiles as a value stock while TELA is a turnaround play — different risk/reward profiles.

TELA carries more volatility with a beta of 0.89 — expect wider price swings.

SYK is growing revenue faster at 11.4% — sustainability is the question.

SYK generates stronger free cash flow (1.9B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (65/100 vs 31/100) and 11.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Tela Bio Inc

HEALTHCARE · MEDICAL DEVICES · USA

TELA Bio, Inc., a medical technology company, focuses on the design, development and commercialization of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is headquartered in Malvern, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?